Headlines | June 12
Markets
Market performance of featured publicly-listed psychedelic companies for the week of June 8th - 12th.
![](https://cdn.prod.website-files.com/5ea1010ae2ce994c214a9e6f/5ee64a716163ecbe6ae66f61_ac928fdb-885d-4263-b87a-0230dded75a2.png)
Deals/Updates
Champignon Brands ($SHRM | $SHRMF | $496)) announced the closing of its bought deal private placement for aggregate gross proceeds of $15,000,375. Press Release. The company selected Dalriada Drug Discovery to advance its IP portfolio (Press Release).
After market close, Champignon also released a corporate update, announcing name change, rebranding and planned spin out. Press Release
MindMed ($MMED | $MMEDF) announced that it is supporting and collaborating on a Phase 2 clinical trial evaluating LSD for the treatment of cluster headaches at University Hospital Basel's Liechti Lab. Press Release
Numinus ($NUMI | $LR23) received a Health Canada licence amendment to produce and extract psilocybin from mushrooms. Press Release
Mydecine Innovations Group ($MYCO | $NLBIF | $0NF) signed a partnership agreement with Applied Pharmaceutical Innovation, a translational commercial drug development institute hosted at the University of Alberta. Press Release
NeonMind Biosciences, a wholly-owned subsidiary of The Yield Growth Corp ($BOSS | $BOSQF | $YG3), announced that they have filed an additional provisional patent application related to the administration of psychedelics to treat compulsive eating disorder, obesity and related illnesses. Press Release
Media
Robin Carhart-Harris published a highly-acclaimed opinion piece in The Guardian discussing the role psychedelic drugs can play in treating depression. Link
Health Europa published an article examining ibogaine as a long term solution to addiction. Link
Psychedelic Finance interviewed Ben Nikolaevsky, CEO of Pure Extracts Corp (Private). Link
Archives
Get the Headlines & Market Updates
Be the first to see new company features, exclusive interviews and breaking news. Subscribe now.